Cleansing Statement

Sydney, 5 November 2026: Australian clinical-stage biotechnology company Noxopharm Limited (ASX:NOX) (Noxopharm or the Company) refers to the Placement announced to ASX in the Appendix 3B dated 2 November 2026 and the Appendix 2A lodged today for the issue of 26,853,552 fully paid ordinary shares in the Company at an issue price of $0.042 per share (**Placement Shares**).

Noxopharm gives this notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

Noxopharm advises that:

1. The Company issued the Placement Shares without disclosure to investors under Part 6D.2 of the Corporations Act.
2. This notice is given under section 708A(5)(e) of the Corporations Act 2001(Cth).
3. As at the date of this notice, the Company has complied with:
   (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
   (b) section 674 and 674A of the Corporations Act.
4. As at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e).

This announcement has been authorised for release by the Board of Noxopharm Limited.

Yours faithfully,

Shawn van Boheemen
Company Secretary

-ENDS-

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Gabriella Hold
The Capital Network
M: 0411 364 382
E: gaby@thecapitalnetwork.com.au

Company Secretary:
Shawn van Boheemen
T: +61 414 903 376
E: shawn.vanboheemen@noxopharm.com

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company developing novel, targeted therapies for chronic inflammation, autoimmune diseases and cancer.

Noxopharm's proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

To learn more, please visit: noxopharm.com

About the Sofra technology platform

Developed from a breakthrough discovery in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.

Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body's defence system.

This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.

Sofra is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment. The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.

Further information and animations: SOF-SKN / SOF-VAC

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.